1. Home
  2. SBET vs MNKD Comparison

SBET vs MNKD Comparison

Compare SBET & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SharpLink Gaming Ltd.

SBET

SharpLink Gaming Ltd.

HOLD

Current Price

$7.14

Market Cap

1.9B

Sector

Technology

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$2.73

Market Cap

793.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBET
MNKD
Founded
1995
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
793.6M
IPO Year
2025
2004

Fundamental Metrics

Financial Performance
Metric
SBET
MNKD
Price
$7.14
$2.73
Analyst Decision
Strong Buy
Buy
Analyst Count
7
8
Target Price
$18.71
$8.56
AVG Volume (30 Days)
6.3M
4.6M
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.02
Revenue
$28,055,000.00
$348,966,000.00
Revenue This Year
$109.16
$35.81
Revenue Next Year
$14.66
$11.89
P/E Ratio
N/A
$131.75
Revenue Growth
666.04
22.23
52 Week Low
$0.19
$2.23
52 Week High
$124.12
$6.51

Technical Indicators

Market Signals
Indicator
SBET
MNKD
Relative Strength Index (RSI) 53.62 45.21
Support Level $6.05 $2.52
Resistance Level $8.34 $4.09
Average True Range (ATR) 0.38 0.12
MACD 0.07 0.12
Stochastic Oscillator 73.29 97.09

Price Performance

Historical Comparison
SBET
MNKD

About SBET SharpLink Gaming Ltd.

SharpLink Gaming Inc is one of the world's largest publicly traded companies to adopt ETH as its primary treasury reserve asset - a move that aligns the Company with the future of digital capital and gives investors direct exposure to Ethereum, the world's smart-contract platform and second largest digital asset.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: